rosiglitazone has been researched along with Metabolic Diseases in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abell, L; Ahmad, S; Apedo, A; Azzara, AV; Brigance, R; Chang, S; Chao, H; Chen, L; Cheng, D; Chu, CH; Cullen, MJ; Dabros, M; Devasthale, P; Dierks, E; Foster, K; Gao, Q; Hangeland, JJ; Harden, D; Harvey, S; Hou, X; Keim, WJ; Kempson, J; Kopcho, L; Lawrence, RM; Li, YX; Ma, Z; Mathur, A; Meng, W; Moore, F; O'Malley, K; Panemangelor, R; Pelleymounter, MA; Robl, JA; Rooney, S; Turdi, H; Wang, W; Whaley, JM; Wu, DR; Ye, XY; Zhao, G | 1 |
| Appendino, G; Calzado, MA; Eugenia Prados, M; Ferreiro-Vera, C; Garrido-Rodriguez, M; Morrugares, R; Muñoz, E; Nadal, X; Palomares, B; Ruiz-Pino, F; Sánchez-Garrido, MA; Tena-Sempere, M; Vazquez, MJ; Velasco, I | 1 |
| Araujo de Baptista, E; Baptista, T; Beaulieu, S; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E | 1 |
| Abbasi, F; Chu, JW; Cooke, JP; Lamendola, C; McLaughlin, TL; Reaven, GM; Stühlinger, MC; Tsao, PS | 1 |
1 trial(s) available for rosiglitazone and Metabolic Diseases
| Article | Year |
|---|---|
Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Double-Blind Method; Female; Fibrinogen; Hemoglobins; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Metabolic Diseases; Middle Aged; Olanzapine; Pilot Projects; Rosiglitazone; Schizophrenia; Statistics as Topic; Thiazolidinediones | 2009 |
3 other study(ies) available for rosiglitazone and Metabolic Diseases
| Article | Year |
|---|---|
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders.
Topics: Animals; Crystallography, X-Ray; Drug Discovery; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Metabolic Diseases; N-Acetylglucosaminyltransferases; Structure-Activity Relationship | 2021 |
Tetrahydrocannabinolic acid A (THCA-A) reduces adiposity and prevents metabolic disease caused by diet-induced obesity.
Topics: 3T3-L1 Cells; Adipogenesis; Adiposity; Animals; Anti-Inflammatory Agents; Cells, Cultured; Diet, High-Fat; Dronabinol; Fatty Liver; HEK293 Cells; Humans; Male; Metabolic Diseases; Mice; Mice, Inbred C57BL; Obesity; PPAR gamma; Rosiglitazone | 2020 |
Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor.
Topics: Adult; Aged; Arginine; Cardiovascular Diseases; Cross-Sectional Studies; Enzyme Inhibitors; Female; Humans; Hypertension; Hypoglycemic Agents; Lipoproteins; Male; Metabolic Diseases; Metabolic Syndrome; Middle Aged; Nitric Oxide Synthase; Regression Analysis; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Vasodilator Agents | 2002 |